A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease.

被引：68

作者：

Feagan, BG

Sandborn, WJ

Baker, JP

Cominelli, F

Sutherland, LR

Elson, CD

Salzberg, B

Archambault, A

Bernstein, CN

Lichtenstein, GR

Heath, PK

Hanauer, SB

机构：

[1] London Clin Trials Res Grp, London, England

[2] Mayo Clin, Rochester, MN USA

[3] Univ Toronto, Toronto, ON, Canada

[4] Univ Virginia, Charlottesville, VA USA

[5] Univ Calgary, Calgary, AB, Canada

[6] Univ Alabama, Birmingham, AL USA

[7] Atlanta Gastroenterol Assoc, Atlanta, GA USA

[8] Univ Montreal, Montreal, PQ, Canada

[9] Univ Manitoba, Winnipeg, MB, Canada

[10] Univ Penn, Philadelphia, PA 19104 USA

[11] Celltech Therapeut Inc, Slough, Berks, England

[12] Univ Chicago Hosp, Chicago, IL 60637 USA

来源：

关键词：

D O I：

10.1016/S0016-5085(00)84761-7

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

3599

引用

页码：A655 / A655

页数：1